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A B S T R A C T
This narrative review is intended to introduce clinicians treating epilepsy and researchers familiar with
mammalian models of epilepsy to experimentally tractable, non-mammalian research models used in
epilepsy research, ranging from unicellular eukaryotes to more complex multicellular organisms. The
review focuses on four model organisms: the social amoeba Dictyostelium discoideum, the roundworm
Caenorhabditis elegans, the fruit ﬂy Drosophila melanogaster and the zebraﬁsh Danio rerio. We consider
recent discoveries made with each model organism and discuss the importance of these advances for the
understanding and treatment of epilepsy in humans. The relative ease with which mutations in genes of
interest can be produced and studied quickly and cheaply in these organisms, together with their
anatomical and physiological simplicity in comparison to mammalian species, are major advantages
when researchers are trying to unravel complex disease mechanisms. The short generation times of most
of these model organisms also mean that they lend themselves particularly conveniently to the
investigation of drug effects or epileptogenic processes across the lifecourse.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy is characterised by recurrent unprovoked epileptic
seizures. The ILAE deﬁnition of an epileptic seizure is a transient
occurrence of signs and/or symptoms due to abnormal excessive or
synchronous neuronal activity in the brain.1 Whilst most epileptic
seizures do not seem to cause signiﬁcant lasting damage, repeated* Corresponding author. Tel.: +44 114 222 2389.
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reor prolonged seizures can cause persistent functional and
morphological change. Around 0.7% of the general population
suffer from epilepsy, and although many patients respond
satisfactorily to the available anti-epileptic drugs (AEDs), around
a third of people with epilepsy do not respond to currently
available treatments.2 There is, therefore, a signiﬁcant unmet need
both for better understanding of the disease process and for new
strategies that enable cost-efﬁcient discovery of new anti-epileptic
drugs. Human genetic studies indicate that defects in a wide
variety of molecular and cellular mechanisms facilitating normal
nervous system development and maintaining neural homeostasis
underlie ictogenetic and epileptogenetic processes.3 For example,
mutations in genes that encode subunits of neurotransmitter
receptors and ion channels may be ictogenetic and epileptogenic,
conﬁrming roles for the synaptic and the intrinsic excitability
machinery in seizure processes.4 In addition, epileptogenicserved.
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STXBP1, PCDH19, TBC1D24, CHD2, SYNGAP1 and ALG13, which
perform diverse roles in cellular processes such as neuronal
morphogenesis, synapse formation, transcriptional regulation and
intercellular signalling within the nervous system,4–6 further
widening the range of molecular mechanisms speciﬁcally impli-
cated in human epilepsy. In order to build on the insights provided
by human molecular genetic analysis, model systems are required
that allow the fundamental mechanisms underlying seizure
phenotypes and therapeutic drug actions to be elucidated. It is
not always necessary to recapitulate human seizure phenotypes in
every respect and indeed, there are many advantages in using
simple models to understand the fundamental biological processes
that underlie seizure generation and mechanisms of drug action.
Moreover, whilst the greater similarities between the nervous
systems of different mammalian species may make rodent models
particularly appropriate for determining likely treatment
responses in humans, variation in the genetic background of
rodent strains can lead to opposing or contradictory results,
confounding experimental studies.7 Rodent models are also more
expensive and require complicated, invasive procedures to analyse
gene functions in seizure processes. In higher non-mammalian
systems, such as zebraﬁsh, the network mechanisms that generate
seizures are likely to be similar to those that underlie seizures in
mammals,8 and many other non-mammalian organisms exhibit
phenotypes with seizure-like characteristics when the balance
between excitatory and inhibitory neurotransmission within the
CNS is perturbed. For some types of anti-epileptic drugs, the
extensive evolutionary conservation of the sequences of their
protein targets means that even unicellular eukaryotes can be
employed for drug screening and mechanism-of-action studies.
Thus, for all of these reasons, a wide variety of species that are
biologically simpler than mammals has begun to be deployed in
epilepsy research.
2. Anti-epileptic drug discovery and pharmacology using
Dictyostelium discoideum
The unicellular social amoeba Dictyostelium has been used as a
simple model system in epilepsy research to elucidate the modes
of action of existing anti-epileptic drugs and then to use this
information to identify new compounds with improved speciﬁcity
and efﬁcacy. D. discoideum is listed by the US National Institute of
Health as a biomedical model system9 and has been used in a range
of biochemical and pharmacogenetics studies to deﬁne the action
of therapeutic compounds in mammalian models.10–12 The key
advantages of this model include: enabling the rapid analysis of
drug effects on normal cell function and on synchronised
development; the screening of mutant cell banks to identify the
genetic basis of drug mechanisms; the analysis of isogenic cell lines
containing ablated or over-expressed proteins to deﬁne a role of
individual or multiple proteins as potential drug targets; and the
use of multiple gram weights of isogenic cell lines for biochemical
analysis. These features enable Dictyostelium to be employed as a
valuable animal replacement model, with a range of methodologi-
cal attributes not available in mammalian models in epilepsy
research.
Sodium valproate is the most commonly prescribed treatment
for epilepsy worldwide,13 but until recently, very little was known
about its mechanism of action as an AED.14 Recent studies showed
that valproic acid regulated the turnover of phosphoinositides in
Dictyostelium at concentrations similar to those found in humans
during treatment for epilepsy.12,15 To investigate the molecular
mechanism underlying this effect, cell lines containing ablated
target proteins involved in phosphoinositide production and
recycling were tested for sensitivity to valproate in an attemptto isolate a mutant lacking the protein target for valproate. The
results of these studies suggested that the molecular target for
valproate in Dictyostelium is likely to be involved in either the
incorporation or transfer of inositol within phosphoinositide
species.15 A structure–activity-based screen of a range of
valproate-like compounds identiﬁed a range of medium chain
fatty acids that inhibited phosphoinositide production in Dictyos-
telium more effectively than valproate. These fatty acids included a
major component of the medium chain triglyceride (MCT)
ketogenic diet, decanoic acid.15 Excitingly, the level of this fatty
acid is elevated in the plasma of children on the ketogenic diet16,17
suggesting a role for decanoic acid in seizure control. The
molecular basis of the therapeutic effect of the MCT ketogenic
diet remains unclear. To improve tolerability, it will be critical to
identify compounds within the diet that help to control seizures
but lack the side-effects and the necessity for the severe dietary
restrictions engendered by the ketogenic diet. Considerable
research has initially focused on one physiological effect of the
diet – the increasing level of ketone body formation in patients.
However, this has since been shown to correlate poorly with
seizure control in animal models.18,19 An alternative effect of the
diet is the accumulation of medium chain fatty acids in blood (in
particular decanoic and octanoic acids). The identiﬁcation of
decanoic acid and a range of octanoic acid derivatives, with similar
effects to valproate on phosphoinositide signalling in Dictyoste-
lium, suggested a common mechanism of action for these
compounds in this simple model, and raised the possibility that
they might also be effective in seizure control. To investigate this
possibility, decanoic and octanoic acids were assessed in a rat
hippocampal slice (PTZ) model of seizures.15,20 A subset of the
tested compounds exhibited strong seizure control activity, with
signiﬁcant improvement over valproate. Compounds with high
activity also showed high structural speciﬁcity, so that, for
example, 4-methyloctanoic, 4-ethyloctanoic, and 2-proplyocta-
noic acid demonstrated strongly improved seizure control,
compared to valproic acid, whereas octanoic acid and 3,7-
dimethyloctanoic acid were ineffective. Some of these novel active
compounds were effective both in a low magnesium (drug-
resistant) model of seizure control and in an in vivo status
epilepticus model.15 The recent advances in this work have
demonstrated that seizure-like activity, induced in primary rat
neurons or in ex vivo hippocampal slices by PTZ, or in vivo by kainic
acid, causes a reduction in the key signalling phosphoinositide,
PIP3, and this reduction is blocked in the presence of valproate.
21
This mechanism, initially identiﬁed in Dictyostelium, provides a
credible new explanation for the anti-epileptic effect of valproate
in seizure control.
Since both enhanced efﬁcacy and safety characteristics must be
considered when introducing new epilepsy treatments, the family
of potent fatty acids was also examined for potential side effects,
including teratogenicity.20 Valproate and related short chain fatty
acids have been well documented to inhibit histone deacetylase
(HDAC) activity,22,23 causing altered gene transcription during
embryonic development, leading to embryonic malformations,
which consequently limits their use in women of childbearing
age due to the increased risk of birth defects.24,25 Assessment of
HDAC inhibition by these potent fatty acids identiﬁed a subset of
compounds that are less likely to cause birth defects through
this mechanism, providing potentially safer treatment during
pregnancy.
The identiﬁcation of phosphoinositide signalling as a target for
anti-epileptic drug discovery has led to the discovery of novel fatty
acids with enhanced activity, including decanoic acid, which is
elevated in the plasma of patients on the MCT ketogenic diet.
Translation of discoveries made in Dictyostelium to mammalian
epilepsy models suggest that this family of novel compounds may
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epilepsy, and highlights the advantages of an innovative 3Rs
approach to epilepsy research.
3. Caenorhabditis elegans models of epilepsy
Caenorhabditis elegans is a non-parasitic, soil-dwelling nema-
tode worm. It mainly exists in a self-fertilising, hermaphrodite
form, although males are present at very low frequencies.
Development from egg to the approximately 1 mm-long adult
takes around 3 days, and adults live for around 3 weeks. From the
pioneering studies of Brenner in the 1960s,26 C. elegans rapidly
became one of the major model organisms used in biology. Indeed,
the genome of C. elegans was the ﬁrst metazoan genome to be fully
sequenced, in 1998. One of the main reasons why Brenner chose C.
elegans was that its simplicity could enable an understanding of
how genes specify the development of the nervous system and
determine behaviour; a goal that was unfeasible with established
animal model organisms. Indeed, the C. elegans nervous system
comprises just 302 neurons, out of a total of 959 cells in the adult
hermaphrodite. It is unique among animals in that the positions
and fates of all of its cells are known, and the 7000 synaptic
connections made by its 302 neurons have been mapped by serial
section electron microscopy. Despite this simplicity, worms
display a surprisingly complex set of behaviours and are capable
of learning. The neurotransmitters that control many of these
behaviours are conserved from worm to human and over 40% of
human disease genes have worm homologues. A number of other
special attributes make C. elegans particularly attractive as a model.
The animal is naturally transparent, and virtually any speciﬁc
neuron type can be visualised in freely moving animals via cell-
speciﬁc promoters driving GFP ﬂuorescence. The ability to grow
thousands of hermaphrodites on agar plates without the need for
mating makes it particularly well suited to high-throughput
chemical and genetic screening. The unique ability to perform
genome-wide knock down of protein expression via RNA
interference simply by feeding the worms transformed versions
of their standard laboratory food source, Escherichia coli, is
particularly powerful in this regard.27 Another advantage is that
homozygous loss-of-function mutations in conserved genes
required for neuronal function are usually viable, in contrast to
other models such as Drosophila, thus facilitating experimental
analysis. There are disadvantages of C. elegans, however, with
regard to its utility as an epilepsy model. Clearly, the extreme
simplicity of the nervous system makes it more difﬁcult to directly
compare to the human disease than with rodent models. In
addition, epilepsy is ultimately deﬁned by episodes of abnormal
electrical activity in the brain, but electrophysiological techniques
are extremely challenging to perform using C. elegans. Finally, there
are some differences between neurons in worms and humans that
may prevent certain lines of epilepsy research – for example,
C. elegans neurons lack voltage-gated sodium channels.28
Despite these caveats, the nematode represents a promising
model with potential to shed light on certain aspects of epilepsy.
Whilst the number of published studies using C. elegans to gain
epileptological insights is relatively small compared to the huge
number of studies using this model organism to explore basic
neurobiology29 or to describe mechanisms of neurodegenera-
tion,30 the pace of epilepsy research with this organism is
beginning to gather momentum. The ﬁrst publications focused
on the worm homologue of the human lis1 gene that, when
mutated, causes the epilepsy-prone disease lissencephaly.31 By
using a particular allele of C. elegans lis-1, Caldwell and colleagues
were able to demonstrate that these mutant worms exhibited
repetitive convulsions when treated with the seizure-inducing
GABA antagonist, pentylenetetrazole (PTZ). Importantly, the lis-1allele used did not display the neuronal migration and architecture
defects evident in lissencephaly, suggesting that alterations in
GABAergic presynaptic vesicle function may underlie the convul-
sions in both worms and humans. Consistent with this notion,
mutations in genes involved in GABA synthesis (unc-25, encoding
glutamic acid decarboxylase), vesicular uptake (unc-47, encoding a
synaptic vesicle GABA transporter) or responsiveness (unc-49,
encoding a GABAA receptor), all resulted in phenotypically similar
convulsions to those seen with the lis-1 allele.31 Interestingly,
these convulsions manifest as repetitive anterior muscle contrac-
tions – so called ‘head-bobbing’, while the posterior part of the
worm is paralysed. In contrast, PTZ treatment of worms with a
mutation in calmodulin-dependent protein kinase (unc-43) causes
full body convulsions, with contraction of both the head and the
tail region of the animal. The GABA-speciﬁc anterior head-bobbing
phenotype was subsequently used in an RNAi screen to identify
additional components of the lis-1 pathway, revealing that several
genes involved in neuronal migration can contribute to the
convulsive phenotype.32 It is likely that cytoskeletal transport
processes are important in this regard, as both microtubule- and
actin-based mechanisms have been implicated due to the effect of
dynein and Rac mutations, respectively.31,33
An alternative C. elegans epilepsy model emerged from studies
of neuronal acetylcholine receptors. A gain-of-function mutation
in the acr-2 gene, which encodes a subunit of the acetylcholine
receptor, was found to cause spontaneous ‘shrinking’ convulsions
in the absence of seizure-inducing agents.34 Interestingly, an
identical mutation in the b1 subunit of the human muscle
acetylcholine receptor causes myasthenia gravis due to creation of
a hyperactive channel. Consistent with this, electrophysiological
analysis of the C. elegans acr-2 mutant revealed increased
cholinergic transmission accompanied by reduced GABAergic
transmission.34 To shed light on how this imbalance in excitato-
ry/inhibitory inputs leads to the convulsive phenotype, a forward
genetic screen was conducted to identify mutations that suppress
the acr-2 mutant seizure phenotype.35 These experiments revealed
that mutation of gtl-2, encoding a member of the transient receptor
potential of the melastatin (TRPM) channel family, virtually
eliminated spontaneous convulsions. Interestingly, GTL-2 is not
expressed in neurons, suggesting that control of systemic ion
homeostasis by non-neuronal TRPM channels enables sophisticat-
ed regulation of neuronal network activity. This may in turn
suggest potentially new therapeutic approaches for epilepsy.
Finally, a C. elegans epilepsy model has recently been developed
that avoids the need to use either PTZ or deﬁned mutants. Instead,
this model simply involves heating the worms to over 26 8C in
solution, which results in repetitive unilateral contractions of the
anterior part of the animal.36 Clearly, the relevance of such heat-
induced phenotypes to human epilepsy is not as obvious as the
PTZ- or mutation-based approaches. Nevertheless, convulsions
were reduced by Baccoside A, a plant-derived compound with
reported anti-epileptic properties, and by mutation of cca-1, the
putative worm homologue of T-type calcium channels.35 This led
to the suggestion that Baccoside A acts to prevent convulsions by
inhibiting CCA-1 channel activity.
The use of C. elegans as a model for epilepsy research is in its
infancy. Nevertheless, the few published studies to date give a hint
of the great potential of the model for combining chemical
screening with genetics, both to uncover underlying disease
mechanisms and to suggest novel therapeutics. The real power of
the nematode model is the ability to do this in a high-throughput,
genome-wide scale that is not feasible with most other model
organisms. For example, genetic screens using RNAi or classical
mutagenesis could be used to isolate genetic suppressors or
enhancers of induced seizures in vivo, as has been done for the acr-
2 mutant described above.35 Similarly, genetic screens could be
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prescribed anti-epileptic drugs whose in vivo targets are unclear.
Alternatively, phenotype-based screening for compounds capable
of preventing convulsions could potentially reveal novel thera-
peutics. The availability of automated video imaging systems
capable of recording worm movement in solution in a high-
throughput manner makes large-scale chemical-genetic screens of
this type feasible.37 Thus, despite its limitations, the simple
nematode worm has signiﬁcant untapped potential to contribute
to epilepsy research.
4. Genetic control of seizure susceptibility in Drosophila
melanogaster
There are several prominent features of the fruit ﬂy,
D. melanogaster, that make it an attractive experimental model
for epilepsy research. The simplicity of its nervous system, rapid
life cycle, fully sequenced genome, and ability to manipulate its
genetics all facilitate the analysis of complex interactions between
genes and behaviour. Moreover, the possibility of performing
electrophysiological recordings at different stages, provides a
relatively new tool to investigate alterations in neuronal activity
during development and/or seizure in this model system.38 It has
been estimated that nearly 75% of disease-related genes in humans
have functional orthologues in ﬂies, establishing Drosophila as a
valuable model system for the study of numerous human diseases,
including epilepsy.39 In wild-type Drosophila, high frequency
electrical stimuli can trigger seizure activity that results in
convulsive spasms which are reminiscent of the motor convulsions
caused by epileptic seizures in humans. Mutations in Drosophila
genes encoding a range of distinct types of proteins, both reduce
the threshold for such electrically-induced seizure onset, and also
render seizure onset sensitive to mechanical shocks, such as a tap
of the culture vial or brief vortexing on a laboratory mixer.40,41
These so-called Bang-Sensitive mutations (BS mutations) affect
genes that encode proteins such as the voltage-sensitive sodium
channel a-subunit (paralytic), ethanolamine kinase (easily
shocked), aminopeptidase N (slamdance), an RNA binding protein
(couch potato), and a LIM-domain transcription factor (prickle).
Seizure onset is usually characterised, in adult ﬂies, by leg shaking,
abdominal muscle contractions, wing-ﬂapping and proboscis
extensions, after which a period of paralysis typically ensues.
This is often followed by tonic-clonic-like convulsive spasms.
Signiﬁcantly, this seizure-like behaviour can be reduced by prior
ingestion of clinically-relevant AEDs.42,43
After a refractory period, during which no further seizures can
be induced, ﬂies recover and re-acquire bang-sensitivity. The BS
phenotype has been used to identify second-site mutations that
suppress this phenotype.41 Such mutations include alleles of the
voltage-gated potassium channel Shaker, the gap junction channel
shaking-B, the voltage-gated sodium channel paralytic, the zinc
ﬁnger transcription factor escargot, and DNA Topoisomerase I. Taken
together, the diversity of gene products whose functions are
affected by BS or Seizure-Suppressor mutations reﬂects the
complexity of the biology underlying seizure susceptibility in
Drosophila.
Interestingly, AEDs such as valproate, phenytoin, gabapentin
and Sodium bromide cause appreciable, albeit variable suppres-
sion of BS phenotypes of the BS mutant easily shocked. In contrast,
the AEDs carbamazepine, ethosuximide and vigabatrin, do not
suppress the BS phenotype of this mutant.44 The speciﬁcity of these
pharmacological effects, together with the varied functions of the
gene products affected in Bang-Sensitive and Seizure-Suppressor
mutants, indicate that seizure onset in ﬂies is a physiologically
complex process, further study of which is likely to yield new
insights to human epilepsy. Moreover, despite the evolutionarydistance, the similarities in the epileptiform activities between
ﬂies and mammals, together with the similar responses of seizures
in these organisms to AEDs, make BS mutants attractive models for
epilepsy research.
Recent studies of the BS mutant slamdance (sda) have yielded
particularly interesting insights into the mechanisms of both
seizures and anti-epileptic drug action. Electrical stimulation of
the larval stage of the BS mutant sda results in extended bouts of
paralysis. Electrophysiological analysis of the CNS in this mutant
reveals increased persistent sodium current (INap) mediated by
voltage-gated sodium (Nav) channels in motor neurons.
38 INap is a
key pharmacological target to control seizures in humans. This
current, which is present in almost all neurons, arises from
incomplete inactivation of Nav channels and acts to potentiate
action potential ﬁring.45,46 An increase in INap has been associated
with both symptomatic46 and idiopathic epilepsy.47 However, the
molecular mechanism underlying INap is not well understood.
Progress in this regard has been complicated by extensive genetic
redundancy: mammalian genomes encode at least nine NaVs. By
contrast, the genome of the fruitﬂy has just one Nav channel
homolog, encoded by paralytic.48,49 This relative simplicity
facilitates a combination of genetic, pharmacological, electrophys-
iological and behavioural techniques to be used in the ﬂy to
understand the mechanistic basis of INap and its contribution to
seizure.
Prior exposure of sda seizure mutant larvae to typical anti-
epileptics (e.g. phenytoin or gabapentin) reduced both INap and
paralysis following electroshock, suggesting an association be-
tween the two. Molecular analysis of the expressed Nav between
wild-type and sda showed a number of changes to the coding
sequence as a direct consequence of differential alternative
splicing in the two differing genetic backgrounds.50 One change
in particular, the choice to include mutually exclusive exons K or L,
is linked to the generation of seizure (paralysis) phenotypes. In
wild-type larvae, 70–80% of Nav channel transcripts contain exon
L (located in homology domain IIIS3-4), while the remainder
contain exon K (that differs from L by 16 residues). By contrast, the
inclusion of L is increased to 100% in sda.51 Heterologous
expression of K- or L-containing splice variants in Xenopus oocytes
shows that these exons have a marked inﬂuence on the magnitude
of the INap current expressed. When present, exon L results in
channels with a signiﬁcantly larger INap.
50 Thus, a change in
alternative splicing of Nav may promote seizure onset in the ﬂy.
Accordingly, prior ingestion of phenytoin, which is sufﬁcient to
rescue seizure, also reversed the increased inclusion of exon L in
sda back to a wild-type level.51
Ingestion of proconvulsants (e.g. picrotoxin) by wild-type larvae
is sufﬁcient to induce a seizure phenotype. Electrophysiological
analysis in such larvae revealed enhancement of synaptic activity
in motor circuitry and, importantly, increased inclusion of exon L in
expressed Nav transcripts. Conversely, seizure behaviour was
reduced in sda larvae following feeding with GABA, an effect that is
associated with both decreased synaptic activity and reduction of
inclusion of exon L.51 Taken together, these observations indicate
that the mechanism regulating the inclusion of exon L, at the
expense of exon K, is activity-dependent. Moreover, increasing
activity promotes inclusion of exon L, which results in larger INap
which further promotes cell excitability.51 This positive feedback
loop provides a possible mechanistic explanation of the clinical
observation in which small-scale paroxysmal activity, if left
untreated, can directly promote subsequent seizures.52
Pasilla (Ps), a KH domain-containing RNA binding protein, was
shown to inﬂuence the splicing balance between exons K and L.53
The inclusion of exon K is signiﬁcantly increased in a Ps loss-of-
function mutant, indicating that the presence of Ps is necessary for
the inclusion of exon L.50 Thus, treatments that reduce the activity
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Ps levels were reduced in the sda mutant background. Knockdown
of Ps, either by loss of one gene copy (ps+/) or expression of ps-
speciﬁc RNAi, was sufﬁcient to diminish both the increased
inclusion of exon L and seizure severity attributable to the sda
mutation.51 Homologues of Ps in mammals are the neuro-
oncological ventral antigen 1 and 2 splice factors (Nova-1 and
Nova-2, respectively). The genomic region in and around exons K
and L contain several putative [T/C]CA[T/C] Nova-recognition
motifs.53,54 Indeed, comparative analyses concluded that the RNA
regulatory maps between Ps and Nova-1/2 are highly conserved
between ﬂies and mammals, suggesting that splicing of mamma-
lian Navs might be regulated by Nova proteins.
54–56 Moreover,
Nova-1/2 are reportedly involved in pilocarpine-induced epilepsy
in the rat model, where pilocarpine promotes the appearance of
spontaneous recurrent seizures after 1–4 weeks. Sodium current
recordings from CA1 pyramidal cells in such animals showed an
associated 1.5-fold increase in INap and a switch to burst ﬁring
within 1 week.46 Alternative splicing of exon 5 in mammalian Navs
(e.g. human Nav1.1) has been shown to be sufﬁcient to modulate
inactivation and alter the magnitude of INap of heterologously
expressed channels.57 Exon 5 (its variants being 5N and 5A)
occupies a congruent region of the channel (homology domain I,
S3–S4) to exons K or L (domain III, S3–S4 that includes the voltage-
sensor) indicative of conservation of function. Importantly, Nova-
recognition motifs ﬂank exon 5 suggesting that this splicing event,
which may inﬂuence the magnitude of INap, is regulated by Nova
splicing factors. Because of this, an analysis of the Nova proteins,
and identiﬁcation of compounds that affect their activity, may have
important consequences for the treatment of human epilepsy.
5. Zebraﬁsh models of epileptic seizures
Over the last ﬁfteen years, the zebraﬁsh has emerged as a
powerful model vertebrate for the molecular genetic and
pharmacological analysis of development, physiology and dis-
ease.58 Its forward genetic tractability stems from its relatively
short generation time, the large size of clutches of offspring
produced by breeding adults, the efﬁciency of germline mutagen-
esis, and the ease of maintaining large numbers of adults in a
relatively small space. Moreover, the capability to perform large
scale forward genetic screens is now matched by the availability of
an array of reverse genetic techniques which allow mutations to be
introduced into speciﬁc genes of interest,59–61 as well as antisense
methods for inhibiting the expression of speciﬁc genes.62 The
accessibility and transparency of its externally developing
embryos and larvae also facilitate the visualisation of gene
expression patterns in live organisms using ﬂuorescent reporter
transgenes. Importantly, the range of molecular tools available for
these high resolution live imaging studies has recently been
expanded to include genetically-encoded ﬂuorescent calcium-
indicator GCaMP proteins, which can reveal the spatio-temporal
activities of excitable cells such as neurons and muscle, in intact,
living zebraﬁsh embryos and larvae.63–65 The ease with which
chemicals can be added to the water in which zebraﬁsh develop
and swim readily facilitates pharmacological interventions. The
recent development of high-speed video tracking systems allow
larval and adult swimming behaviours to be recorded, measured
and analysed in detail. Thus, combining such pharmacological and
behavioural techniques with imaging technology, mutations and
transgenes offers the possibility of elucidating the neural mecha-
nisms that regulate a remarkable range of normal and pathological
behavioural phenotypes, including fear, aggression, sociality,
reproductive dominance and learning, as well as anxiety, addic-
tion, ADHD and epilepsy.66,67 The small size of the embryonic and
larval stages, combined with the many advantages listed above,makes the zebraﬁsh particularly attractive for high-throughput in
vivo chemical screens for novel bioactive molecules in a high
density, multi-well plate format. This combination of intrinsic
biological features, together with the tools and technologies now
available for the zebraﬁsh, will enable powerful new approaches
for investigating nervous system development, physiology and
disease processes, as well as facilitating the discovery of new
therapeutic drugs. Exposure of zebraﬁsh embryos, larvae or adults
to classical chemical convulsant agents, such as the GABAA
receptor inhibitor Pentylenetetrazole (PTZ), rapidly induces
vigorous locomotor convulsions, along with epileptiform electrical
discharges in the brain that can be monitored by local ﬁeld
potential recordings from electrodes inserted into the tectum68 or
resting on the skin.69 These convulsions are highly similar to those
elicited by epileptic seizures in rodent brain slices and in human
epilepsy patients, and the electrographic analysis of seizures in
zebraﬁsh larval stages reveals both large amplitude ictal dis-
charges and small amplitude interictal discharges as components
of the convulsant-induced neural activity.68,70 Similar studies in
adults conﬁrm that PTZ treatment induces bouts of hyperactivity,
spasms, as well as circular and corkscrew swimming behaviour
that is accompanied by a large increase in serum cortisol levels,
consistent with the induction of stressful epileptic seizures.71
Moreover, an EEG technique has recently been developed for
monitoring PTZ-induced seizures in intact adult zebraﬁsh.72
Interestingly, administration of known anticonvulsants efﬁciently
suppresses both convulsions and the epileptiform discharges in
convulsant-treated embryos and larvae, further underscoring the
similarity of the zebraﬁsh epileptic seizures to those experienced
by rodents and human patients.65,68,73,74 One of the hallmarks of
seizure onset in mammals is the vigorous and rapid induction of a
programme of immediate-early gene transcription in speciﬁc
regions of the brain.75,76 A similar programme of rapidly induced
gene transcription, which includes transcription factors such as
cfos and npas4, is observed in the nervous system and skeletal
muscle of PTZ-treated zebraﬁsh embryos and larvae.65,68 The
biological signiﬁcance of these transcriptional changes remains
incompletely understood, although expression of genes such as
cfos is neuroprotective in rodents,77 and in cultured mammalian
cells, npas4 promotes the formation of GABAergic inhibitory
synapses and regulates the balance between excitatory and
inhibitory activity within neural circuits,78,79 suggesting that at
least some of these genes may play protective, homeostatic
functions that limit the adverse, potentially excitotoxic effects of
seizures. Seizure-induced gene expression can be readily detected
in zebraﬁsh embryos by whole-mount in situ hybridisation, which
provides convenient markers for the onset of seizures that are
particularly useful for high throughput chemical screens to
identify compounds with anticonvulsant activities.65 The regula-
tory relationships and spatio-temporal in vivo expression patterns
of many seizure-induced genes remains poorly characterised, and
so further studies of these genes in zebraﬁsh could enable their in
vivo functional interrelationships to be determined relatively
rapidly.
Zebraﬁsh models of speciﬁc epilepsies have potential for
understanding disease mechanisms and identifying therapeutics.
Inherited childhood epilepsy syndromes are often particularly
intractable conditions. These rare syndromes have a major impact
on the patients and their families but for many of these disorders,
little is known about how the causative mutation results in
epilepsy or the other disease symptoms. In the following sections
we provide an overview of the zebraﬁsh models of inherited
epilepsies that have been generated to date.
Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is
associated with progressive neurodegeneration in children, and
is perhaps one of the most challenging types of inherited epilepsy
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of LINCL was developed. Also known as CLN2 disease, LINCL is
caused by loss-of-function mutations in the CLN2 gene encoding
Tri-peptidyl peptidase 1 (TPP1),80 and interestingly, the majority of
symptoms and pathologies found in LINCL are also present in the
zebraﬁsh tpp1 mutant.81 Thus, tpp1 homozygous mutant larvae at
72 hours post-fertilisation (hpf) exhibit much more frequent and
prolonged bouts of movement than wild-type siblings. At later
stages, tpp1 mutants become immobile and unresponsive to touch,
making the detection of seizures more challenging. However, a
non-invasive electroencephalography method has recently been
used to demonstrate that epileptic seizure-like activity is readily
detectable within the tpp1 mutant CNS (C. Russell, unpublished).
Autosomal Dominant Partial Epilepsy with Auditory Features
(ADPEAF) is caused by mutation of the LGI1 gene, of which there
are two orthologues in zebraﬁsh, lgi1a and lgi1b. Morpholino-
mediated knockdown of lgi1a increased basal locomotor activity
and enhanced the convulsive movements elicited by exposure to
PTZ,82 whereas morpholino-mediated knockdown of lgi1b did not
increase basal locomotor activity of zebraﬁsh larave, but did cause
sensitisation to a PTZ-induced seizure-associated locomotor
convulsive behaviour.83
Lowe Syndrome is an X-linked Oculocerebrorenal syndrome
caused by mutation of a gene encoding OCRL1, a type II inositol
polyphosphate 5-phosphatase involved in phosphoinositide me-
tabolism, and characterised by multiple neurological abnormali-
ties, including cystic lesions in the brain and seizures. ocrl1
homozygous mutant adult zebraﬁsh develop gliosis and cystic
brain lesions reminiscent of those in Lowe Syndrome patients, and
mutant larvae exhibit temperature-sensitive electrographic sei-
zure-like activity in the developing brain.84
The development of a larval zebraﬁsh model for Epilepsy,
Ataxia, Sensorineural deafness and Tubulopathy (EAST) syn-
drome,85 also known as Seizures, Sensorineural deafness, Ataxia,
Mental retardation, and Electrolyte imbalance (SeSAME) syn-
drome,86 offers new hope for improved understanding of the
pathogenetic mechanisms underlying this disorder. This syndrome
is caused by mutations in an inwardly-rectifying potassium
channel called KCNJ10 (previously known as Kir4.1), which most
likely cause partial loss-of-function phenotypes. Recent experi-
ments using an antisense morpholino to knock-down kcnj10
function in zebraﬁsh revealed that morphant larvae exhibited
excessive spontaneous tail movements at 30 hpf, and by 120 hpf,
abnormally long bursts of locomotion during free-swimming that
were followed by a loss of posture.87 Subsequent EEG recordings
demonstrated that this zebraﬁsh model responded positively to
pentobarbitone but not diazepam,69 thus illustrating the relevance
of these studies to understanding epilepsy mechanisms and
identifying treatments.
Mutations in genes encoding KQT-like potassium voltage-gated
channel subfamily members KCNQ2 and KCNQ3 are associated with
Benign Familial Neonatal Convulsions, which although not fatal,
persist throughout life. Pharmacological inhibition of these
channels elicited burst-like electrical discharges in the brain, as
did microinjection of morpholinos targeted against the zebraﬁsh
orthologues of either KCNQ2 or KCNQ3.88 Burst-like discharges are
also typical of the zebraﬁsh Notch pathway mutant, mindbomb,
which encodes an E3 Ubiqitin Ligase that is related to the gene
affected in Angelman Syndrome, in which seizures are a
characteristic feature.89
Functional deﬁcits in voltage-gated sodium channels are
implicated in many epilepsies, and mutations in the human
sodium channel subunit gene SCN1A cause Dravet Syndrome, a
severe, intractable form of childhood epilepsy. Recently, a loss-of-
function recessive mutation in a zebraﬁsh orthologue of SCN1A was
described.90 The usefulness of this genetic model for anti-epilepticdrug discovery was exempliﬁed through the identiﬁcation of the
FDA-approved, histamine antagonist Clemizole as a potent
anticonvulsant, in a drug re-proﬁling screen carried out with the
scn1Lab mutant.90 Such in vivo re-purposing screens of existing
drug collections for new therapeutic applications may be a
particularly cost-effective and rapid approach to drug discovery,
which could complement more established, but costly, de novo
lead identiﬁcation strategies.
Taken together, the recent progress in creating a range of new
zebraﬁsh models of human epilepsy is helping to advance
understanding into the pathogenetic mechanisms underlying this
group of devastating neurological disorders, and identify new
candidate drugs. As more new mutations are reported in novel
human epilepsy genes, the application of techniques for targeted
mutagenesis of zebraﬁsh genes, using TALENs and CRISPRs will
provide additional models for use in epilepsy research.59,60
Moreover, recent studies showing that mutation of the zebraﬁsh
Notch pathway component mind bomb causes epileptic seizures in
larvae implicate fundamental developmental mechanisms in
epileptogenesis89 and raise the possibility that additional insights
from fundamental developmental biology could also help to
improve understanding of epilepsy in the future.
6. Summary
A broad range of non-mammalian model laboratory organisms
have been established as genetically and pharmacologically highly
tractable in vivo systems for experimental studies of epilepsy. As
discussed in this review, the biological relevance of each of these
model systems to human epilepsy has been extensively validated
and documented in the research literature. Many non-mammalian
organisms were ﬁrst used in experiments to elucidate develop-
mental mechanisms. In contrast to mammals, these model
organisms can be maintained relatively simply and cheaply in
the laboratory, and the comparative ease with which mutations in
genes of interest can be created, along with the availability of tools
for monitoring cell behaviours, make these organisms very
amenable to gene function analysis. Their tractability for large-
scale pharmacological screens also makes them particularly
suitable for developing models of human diseases which can then
be employed in drug discovery.
The non-mammalian models discussed here have distinct
strengths and limitations which complement those of mammalian
models of epilepsy. Thus, whilst the social amoeba D. discoideum
lacks a nervous system and consequently has no physiological
equivalent of an epileptic seizure, the great simplicity of this
organism has real advantages for elucidating biochemical path-
ways and the mechanism of drug action. By contrast, the
roundworm C. elegans, fruit ﬂy D. melanogaster and zebraﬁsh
Danio rerio have nervous systems that exhibit behaviours which
are equivalent to epileptic seizures in humans, and their
anatomical and physiological simplicity, taken together with their
ease of maintenance at relatively low cost, help rather than hinder
research efforts to understand disease mechanisms. As illustrated
in this review, research using non-mammalian models has the
potential to reduce the need for research using physiologically
more complex species, but it will not replace all research using
mammalian models in the foreseeable future. Nevertheless, the
laboratory organisms discussed here are likely to play growing
roles in helping to elucidate mechanisms of epileptogenesis and in
identifying new classes of antiepileptic drugs.
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